Boehringer, LEO ink deal for IL-36 drug; Bayer’s Kerendia gets another indication
Plus, news about Illimis Therapeutics and Azurity:
Boehringer Ingelheim, LEO Pharma sign €90M upfront pact: The deal focuses on Spevigo, an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
